Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 22

Sort by

Sort Order Select

Journal Articles

Final Clinical Results of a Phase II Study of High Dose Cytarabine Followed By Pembrolizumab in Relapsed/Refractory AML

Blood (2019) 134 (Supplement_1): 831.

https://doi.org/10.1182/blood-2019-126065

Published: 2019

Journal Articles

Effect of Pulmonary Hypertension and Other Cardiovascular Diseases in Overall Prognosis of Patients with Myelofibrosis

Juan Lopez-Mattei, MD, Srdan Verstovsek, MD PhD, Cezar Iliescu, MD, Karan Bhatti, MD, Nicolas Palaskas, MD, Peter Kim, MD, Bryan Gray, D.O., Saadia Faiz, MD

Blood (2018) 132 (Supplement 1): 4310.

https://doi.org/10.1182/blood-2018-99-118900

Published: 2018

Journal Articles

Ten-Day Decitabine Treatment in AML Associated with Reversible Non-Ischemic Cardiomyopathy

Bhavisha Patel, MD, Barac Ana, MD, Kelly W. Fitzpatrick, MD, Aarthi Shenoy, MD

Blood (2017) 130 (Supplement 1): 5032.

https://doi.org/10.1182/blood.V130.Suppl_1.5032.5032

Published: 2017

Journal Articles

Effect of Anthracycline Dose on Acute Anthracycline Induced Cardiotoxicity in Patients with Acute Myeloid Leukemia Undergoing Hematopoietic Stem Cell Transplantation

Oren Pasvolsky, MD, Olga Morelli, MD, Uri Rozovski, Moti Vaturi, MD, Ofir Wolach, MD, Irina Amitai, MD, Iuliana Vaxman, MD, Roy Ratzon, MD, Moshe Yeshurun, Zaza Iakobishvili, MD, Ran Kornowski, MD, Pia Raanani

Blood (2017) 130 (Supplement 1): 3861.

https://doi.org/10.1182/blood.V130.Suppl_1.3861.3861

Published: 2017

Journal Articles

Brentuximab Vedotin with R-CHP Chemotherapy As Frontline Treatment for Patients with CD30 Positive Primary Mediastinal Large B-Cell, Diffuse Large B-Cell, and Grey Zone Lymphomas: Results of a Phase I/II Multisite Trial

Jakub Svoboda, MD, Daniel J. Landsburg, MD, Sunita Dwivedy Nasta, MD, Stefan Klaus Barta, MDMRCP,MS, Nadia Khan, MD, Henry C. Fung, FRCP,MBBChir, Carlyn Rose Tan, MD, Joanne Filicko-O'Hara, MD, Sameh Gaballa, MD, Lauren Elizabeth Strelec, BA, Sarah J. Nagle, Steven M. Bair, MD, Sheryl Mitnick, MPH, RN, Terease S. Waite, PhD RN, MBE, Rachel Lynn Sargent, MD, Agata M. Bogusz, MDPhD, Ziver Sahin, MD, Anthony R. Mato, MD, Stephen J. Schuster, MD

Blood (2017) 130 (Supplement 1): 191.

https://doi.org/10.1182/blood.V130.Suppl_1.191.191

Published: 2017

Journal Articles

Diastolic Dysfunction Is Associated with Impaired Cardiopulmonary Exercise Performance in Sickle Cell Disease

Tarek Alsaied, MD MSc, Omar Niss, MD, Adam Powell, MD, Robert Fleck, MD, Punam Malik, MD, Clifford Chin, MD, Charles T. Quinn, MD MS, Michael D Taylor

Blood (2017) 130 (Supplement 1): 3547.

https://doi.org/10.1182/blood.V130.Suppl_1.3547.3547

Published: 2017

Journal Articles

Diffuse Myocardial Fibrosis Is a Common Feature of Sickle Cell Anemia That Is Associated with Diastolic Dysfunction and Restrictive Cardiac Physiology

Omar Niss, MD, Michael D. Taylor, MD, Robert Fleck, MD, Tarek Alsaied, MD, Jeffrey Towbin, MD, Punam Malik, MD, Charles T. Quinn, MD MS

Blood (2016) 128 (22): 8.

https://doi.org/10.1182/blood.V128.22.8.8

Published: 2016

Journal Articles

Diastolic Dysfunction with Normal Heart T2* in Thalassemia Major with Heart Failure. a Single Centre Study

Luigi Mancuso, MD, Angela Vitrano, PhD, Massimiliano Sacco, Dr, Andrea Mancuso, MD, Antonietta Ledda, MD, Aurelio Maggio, MD

Blood (2016) 128 (22): 2457.

https://doi.org/10.1182/blood.V128.22.2457.2457

Published: 2016

Journal Articles

Effect of Dexrazoxane on Heart Function Among Long-Term Survivors of Childhood Leukemia and Lymphoma: A Report from the Children's Oncology Group (COG)

Eric J Chow, MD MPH, David R. Doody, MS, Saro H. Armenian, DO, MPH, Sanjeev Aggarwal, MD, K. Scott Baker, MD MS, Smita Bhatia, MD MPH, Nancy A. Blythe, BA, Louis S. Constine, MD, David R. Freyer, DO, MS, Lisa M. Kopp, DO, Wendy M. Leisenring, ScD, Nao Sasaki, MD, Lynda M. Vrooman, MD MSc, Barbara L. Asselin, MD, Cindy L. Schwartz, MD MPH, Steven E. Lipshultz, MD FAAP, FAHA

Blood (2016) 128 (22): 696.

https://doi.org/10.1182/blood.V128.22.696.696

Published: 2016

Journal Articles

Reversible Cardiotoxicity Associated with Carfilzomib Use in Patients with Multiple Myeloma

Tania Jain, M.B.,B.S, Hemalatha Narayanasamy, M.B.B.S., Joseph Mikhael, MD, Craig B. Reeder, MD, P. Leif Bergsagel, MD, Angela Mayo, P.A.-C., M.S., A. Keith Stewart, MBChB, Farouk Mookadam, M.B., B.Ch., Rafael Fonseca, MD

Blood (2016) 128 (22): 2126.

https://doi.org/10.1182/blood.V128.22.2126.2126

Published: 2016

Journal Articles

Mice with Platelet/Megakaryocyte-Specific Deletion of TGF-β1 Are Partially Protected from Liver Fibrosis in a CCl 4 -Induced Liver Injury Model

Shahrouz Ghafoory, PhD, Rohan Varshney, PhD, Jasimuddin Ahamed, PhD

Blood (2016) 128 (22): 414.

https://doi.org/10.1182/blood.V128.22.414.414

Published: 2016

Journal Articles

Nonmyeloablative Hematopoietic Stem Cell Transplantation Improves a Marker of Diastolic Dysfunction in Patients with Sickle Cell Disease

Courtney Fitzhugh, MD, Hwaida Hannoush, MD, Vandana Sachdev, MD, Rosario Di Maggio, MD, Wynona Coles, RRT, Mary Link, RN, Evan Katradis, Xiongce Zhao, PhD, John F. Tisdale, MD, Matthew Hsieh, MD

Blood (2014) 124 (21): 4072.

https://doi.org/10.1182/blood.V124.21.4072.4072

Published: 2014

Journal Articles

A Phase I/II Study Of Cytarabine Or Azacitidine In Combination With Tosedostat In Older Patients With AML Or High-Risk MDS

Courtney D. DiNardo, MD, Hagop M Kantarjian, MD, Farhad Ravandi, MD, Marina Konopleva, MD, PhD, Tapan M. Kadia, MD, Gautam Borthakur, MD, Naval G. Daver, MD, Menda Durand, MSN, RN, Silvia Rivera, MS, Alfonso Quintás-Cardama, MD, Guillermo Garcia-Manero, MD, Jorge E. Cortes, MD

Blood (2013) 122 (21): 2698.

https://doi.org/10.1182/blood.V122.21.2698.2698

Published: 2013

Journal Articles

Assessment Of Endothelial Damage and Cardiac Injury In a Mouse Model Mimicking Thrombotic Thrombocytopenic Purpura

Maelle Le Besnerais, Julie Favre, PhD, Cecile V. Denis, PhD, Bernard Lenormand, Paul Mulder, PhD, Lionel Nicol, PhD, Agnes Veyradier, MD PhD, Alexandra Schiviz, DVM, David G Motto, MD, PhD, Herve Levesque, MD PhD, Paul Coppo, MD PhD, Vincent Richard, PhD, Ygal Benhamou, MD

Blood (2013) 122 (21): 447.

https://doi.org/10.1182/blood.V122.21.447.447

Published: 2013

Journal Articles

Changes in Plasma TGF-β1 Levels in a Murine Model of Aortic Stenosis (Surgical Constriction of the Ascending Aorta) in C57Bl/6 (wild-type) Mice and Mice with a Targeted Deletion of Platelet TGF-β1

Wei Wang, MD, Alexander Meyer, Barry S. Coller, MD, Jasimuddin Ahamed, PhD

Blood (2012) 120 (21): 1065.

https://doi.org/10.1182/blood.V120.21.1065.1065

Published: 2012

Journal Articles

Platelet TGF-β1 contributions to plasma TGF-β1, cardiac fibrosis, and systolic dysfunction in a mouse model of pressure overload

Alexander Meyer, Wei Wang, Jiaxiang Qu, Lori Croft, Jay L. Degen, Barry S. Coller, Jasimuddin Ahamed

Blood (2012) 119 (4): 1064–1074.

https://doi.org/10.1182/blood-2011-09-377648

Published: 2012

Includes: Supplemental data

Journal Articles

Vorinostat in Combination with Pegylated Liposomal Doxorubicin (PLD) and Bortezomib (B) in Patients with Relapsed/Refractory Multiple Myeloma (R/R MM): Final Results of a Phase I Study,

Peter M. Voorhees, MD, Cristina Gasparetto, MD, Keren Osman, MD, Kristy L. Richards, PhD, MD, Madlyn Ferraro, RN, OCN, CCRC, Reynaldo Garcia, RN, Jennifer MacLean, RN, OCN, Diane Winans, CCRP, Dominic Moore, PhD, John Strader, PA-C, Robert Z. Orlowski, MD, PhD, David Duane Hurd, MD

Blood (2011) 118 (21): 3985.

https://doi.org/10.1182/blood.V118.21.3985.3985

Published: 2011

Journal Articles

Mice with Megakaryocyte-Specific Deletion of TGF-β1 Are Partially Protected From Developing Cardiac Fibrosis and Systolic Dysfunction in a Pressure Overload Model

Alexander Meyer, Wei Wang, MD, Jay L. Degen, PhD, Barry S. Coller, MD, Jasimuddin Ahamed, PhD

Blood (2011) 118 (21): 362.

https://doi.org/10.1182/blood.V118.21.362.362

Published: 2011

Journal Articles

Phase II Study of Bortezomib Added to Standard Daunorubicin and Cytarabine Induction and Dose Escalation of Bortezomib with Intermediate-Dose Cytarabine Consolidation Therapy for Patients with Previously Untreated Acute Myeloid Leukemia Age 60–75 Years: Cancer and Leukemia Group B (CALGB) Study 10502

Eyal C Attar, M.D., Kathleen A. Donohue, M.A., Philip C. Amrein, MD, Martha Wadleigh, MD, Daniel J DeAngelo, MD, PhD, Jonathan E Kolitz, MD, Bayard L. Powell, MD, Peter M Voorhees, M.D., Eunice S. Wang, MD, William Blum, MD, Allison Booth, Richard M Stone, M.D., Barry K Moser, Ph.D., Richard Larson, M.D.

Blood (2010) 116 (21): 331.

https://doi.org/10.1182/blood.V116.21.331.331

Published: 2010

Journal Articles

Results of a Phase I Study of Vorinostat In Combination with Pegylated Liposomal Doxorubicin and Bortezomib In Patients with Relapsed/Refractory Multiple Myeloma

Peter M Voorhees, M.D., Cristina Gasparetto, MD, Keren Osman, MD, Kristy Richards, PhD, MD, Madlyn Ferraro, RN, OCN, CCRC, Reynaldo Garcia, RN, OCN, Jennifer MacLean, RN, Diane Winans, Dominic Moore, PhD, John Strader, Robert Z. Orlowski, MD, PhD, David Duane Hurd, MD

Blood (2010) 116 (21): 1955.

https://doi.org/10.1182/blood.V116.21.1955.1955

Published: 2010

NARROW

Final Clinical Results of a Phase II Study of High Dose Cytarabine Followed By Pembrolizumab in Relapsed/Refractory AML

Effect of Pulmonary Hypertension and Other Cardiovascular Diseases in Overall Prognosis of Patients with Myelofibrosis

Ten-Day Decitabine Treatment in AML Associated with Reversible Non-Ischemic Cardiomyopathy

Effect of Anthracycline Dose on Acute Anthracycline Induced Cardiotoxicity in Patients with Acute Myeloid Leukemia Undergoing Hematopoietic Stem Cell Transplantation

Brentuximab Vedotin with R-CHP Chemotherapy As Frontline Treatment for Patients with CD30 Positive Primary Mediastinal Large B-Cell, Diffuse Large B-Cell, and Grey Zone Lymphomas: Results of a Phase I/II Multisite Trial

Diastolic Dysfunction Is Associated with Impaired Cardiopulmonary Exercise Performance in Sickle Cell Disease

Diffuse Myocardial Fibrosis Is a Common Feature of Sickle Cell Anemia That Is Associated with Diastolic Dysfunction and Restrictive Cardiac Physiology

Diastolic Dysfunction with Normal Heart T2* in Thalassemia Major with Heart Failure. a Single Centre Study

Effect of Dexrazoxane on Heart Function Among Long-Term Survivors of Childhood Leukemia and Lymphoma: A Report from the Children's Oncology Group (COG)

Reversible Cardiotoxicity Associated with Carfilzomib Use in Patients with Multiple Myeloma

Mice with Platelet/Megakaryocyte-Specific Deletion of TGF-β1 Are Partially Protected from Liver Fibrosis in a CCl 4 -Induced Liver Injury Model

Nonmyeloablative Hematopoietic Stem Cell Transplantation Improves a Marker of Diastolic Dysfunction in Patients with Sickle Cell Disease

A Phase I/II Study Of Cytarabine Or Azacitidine In Combination With Tosedostat In Older Patients With AML Or High-Risk MDS

Assessment Of Endothelial Damage and Cardiac Injury In a Mouse Model Mimicking Thrombotic Thrombocytopenic Purpura

Changes in Plasma TGF-β1 Levels in a Murine Model of Aortic Stenosis (Surgical Constriction of the Ascending Aorta) in C57Bl/6 (wild-type) Mice and Mice with a Targeted Deletion of Platelet TGF-β1

Platelet TGF-β1 contributions to plasma TGF-β1, cardiac fibrosis, and systolic dysfunction in a mouse model of pressure overload

Vorinostat in Combination with Pegylated Liposomal Doxorubicin (PLD) and Bortezomib (B) in Patients with Relapsed/Refractory Multiple Myeloma (R/R MM): Final Results of a Phase I Study,

Mice with Megakaryocyte-Specific Deletion of TGF-β1 Are Partially Protected From Developing Cardiac Fibrosis and Systolic Dysfunction in a Pressure Overload Model

Results of a Phase I Study of Vorinostat In Combination with Pegylated Liposomal Doxorubicin and Bortezomib In Patients with Relapsed/Refractory Multiple Myeloma

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only